AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its MECFS and Long COVID Programs
| AIM Stock | USD 0.22 0.01 4.35% |
About 63% of AIM ImmunoTech's investor base is looking to short. The analysis of the overall investor sentiment regarding AIM ImmunoTech suggests that many traders are alarmed. AIM ImmunoTech's investing sentiment overview a quick insight into current market opportunities from investing in AIM ImmunoTech. Many technical investors use AIM ImmunoTech stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
AIM |
OCALA, Fla., April 15, 2024 -- AIM ImmunoTech Inc. today announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop Ampligen as a
Read at benzinga.com
 |
AIM ImmunoTech Fundamental Analysis
We analyze AIM ImmunoTech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AIM ImmunoTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AIM ImmunoTech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earning
Price To Earning Comparative Analysis
AIM ImmunoTech is currently under evaluation in price to earning category among its peers. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
AIM ImmunoTech Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with AIM ImmunoTech stock to make a market-neutral strategy. Peer analysis of AIM ImmunoTech could also be used in its relative valuation, which is a method of valuing AIM ImmunoTech by comparing valuation metrics with similar companies.
Peers
AIM ImmunoTech Related Equities
| APM | Aptorum Group | 10.71 | ||||
| PULM | Pulmatrix | 5.66 | ||||
| TNXP | Tonix Pharmaceuticals | 3.13 | ||||
| CAPR | Capricor Therapeutics | 1.86 | ||||
| KPRX | Kiora Pharmaceuticals | 0.79 | ||||
| BCDA | Biocardia | 0.46 | ||||
| SLNO | Soleno Therapeutics | 0.48 | ||||
| JAGX | Jaguar Animal | 1.20 | ||||
| VRAX | Virax Biolabs | 3.27 | ||||
| CLRB | Cellectar Biosciences | 4.00 | ||||
| FBRX | Forte Biosciences | 4.66 | ||||
| AKTX | Akari Therapeutics | 4.92 | ||||
| VXRT | Vaxart | 6.10 | ||||
| REVB | Revelation Biosciences | 21.88 |
Check out AIM ImmunoTech Hype Analysis, AIM ImmunoTech Correlation and AIM ImmunoTech Performance. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.